Search

Displaying results 3771 - 3780 of 8974 in total
  1. Drug

    Carbocromen

    go.drugbank.com/drugs/DB13279
    ApprovedWithdrawn

    Carbocromen was marketed for use in Germany as a vasodilator, however, it has been discontinued due to the risk of arrhythmia development [L5635].

  2. Drug

    Rolapitant

    go.drugbank.com/drugs/DB09291
    ApprovedInvestigational

    Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. … Unlike other available NK-1 receptor antagonists, rolapitant is not an inhibitor of Cytochrome P450 enzyme CYP3A4 and has a long elimination half-life, allowing a single dose to prevent both acute and

  3. Drug

    Drostanolone propionate

    go.drugbank.com/drugs/DB14655
    ApprovedIllicit

  4. Drug

    Pomaglumetad methionil

    go.drugbank.com/drugs/DB05096
    Investigational

    For LY2140023, the active substance, LY404039, is thought to work by reducing the presynaptic release of another neurotransmitter, glutamate, in brain regions where mGlu2/3 receptors are expressed. … Further studies are planned or are ongoing to learn more about the safety and effectiveness, including determining an optimal therapeutic dose for LY2140023.

  5. Drug

    Sonidegib

    go.drugbank.com/drugs/DB09143
    ApprovedInvestigational

    Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma.

  6. Drug

    Fluspirilene

    go.drugbank.com/drugs/DB04842
    ApprovedWithdrawn

    A long-acting injectable antipsychotic agent used for chronic schizophrenia.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  7. Drug

    Rimiducid

    go.drugbank.com/drugs/DB04974
    Investigational

    It was designed to overcome limitations of current cellular immunotherapies used for cancer and other blood disorders by enhancing the control of the immune cell activity and function. … [A187496,L9521] The combination use of rimiducid with immunotherapies for enhanced therapeutic effectiveness is currently under investigation.

  8. Drug

    Copper Cu-64

    go.drugbank.com/drugs/DB13980
    Approved

    Copper-64 is a radiopharmaceutical usually found in the +2 oxidation state as the complexes including the +1 state tend to be more unstable.

    Mixtures: Dermamed Nutrition for troubled skin
  9. Drug

    Chromous sulfate

    go.drugbank.com/drugs/DB14530
    Approved

  10. Drug

    MPI-674

    go.drugbank.com/drugs/DB05749
    Experimental

    AIs are a class of drugs that reduce the amount of estrogen circulating in the body by binding to and inhibiting the enzyme aromatase, which is responsible for converting certain hormones to estrogen. … It is developed for the treatment of several serious women’s health conditions including endometrial thinning prior to endometrial ablations in premenopausal women with abnormal uterine bleeding (AUB).